Drug Development

Webinar Date/Time: Wed, May 15, 2024 2:00 PM EDT

Genmab's acquisition of ProfoundBio will boost its clinical and preclinical pipeline of ADCs for targeted cancer treatment.

Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.

Experts believe it is likely cancer cells are more common in the body than previously thought, but typically caught early and removed in the body’s cancer-immune cycle. When the system is in good working order (and protecting us), dead cancer cells release neoantigens.

FDA granted fast track designation to nipocalimab, which J&J is developing for helping alloimmunized pregnant adults treat FNAIT, a rare disease that poses risk to the fetus or newborn.

FDA has approved AstraZeneca's Ultomiris, marking the first and only long-acting C5 complement inhibitor for patients with NMOSD.

Webinar Date/Time: Tue, Apr 16, 2024 11:00 AM EDT

Webinar Date/Time: Thu, Apr 25, 2024 11:00 AM EDT

Webinar Date/Time: Wed, May 8, 2024 11:00 AM EDT

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Webinar Date/Time: Wed, Apr 24, 2024 11:00 AM EDT

EMA has validated two MAAs submitted by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan in two types of cancer.

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

Webinar Date/Time: Tue, Mar 26, 2024 11:00 AM EDT

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

Webinar Date/Time: Tue, Apr 9, 2024 11:00 AM EDT

Webinar Date/Time: Friday, April 5, 2024 at 11amEDT | 10am CDT | 8am PDT

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

The power of collaboration is a critically important for the bio/pharma industry.

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Activation and expansion are essential for success in both autologous and allogeneic therapies.

CordenPharma’s new starter kits are designed to enable effective formulation in the development of mRNA-based therapeutics.

This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.

Webinar Date/Time: Tue, Apr 9, 2024 2:00 PM EDT

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

Webinar Date/Time: Thu, Mar 14, 2024 2:00 PM EDT

Webinar Date/Time: Wed, Mar 27, 2024 11:00 AM EDT